TYME · Tyme Technologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.96M | $4.18M | $3.46M | $3.50M | $4.72M | $3.55M | $4.71M | $2.72M | $3.45M | $3.12M |
| SG&A | $4.65M | $2.47M | $2.42M | $2.43M | $3.06M | $2.32M | $2.61M | $3.46M | $3.09M | $3.13M |
| Total Operating Expenses | $6.61M | $6.65M | $5.89M | $5.93M | $7.77M | $5.87M | $7.32M | $6.18M | $6.54M | $6.25M |
| D&A | - | - | - | - | $1.3K | - | - | $1.3K | - | - |
| Operating Income | ($6.61M) | ($6.65M) | ($5.89M) | ($5.93M) | ($7.77M) | ($5.87M) | ($7.32M) | ($6.18M) | ($6.54M) | ($6.25M) |
| Interest Expense | $11.9K | $21.3K | $16.3K | $19.4K | $29.4K | $22.5K | $26.0K | $33.0K | $26.3K | $29.2K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.49M) | ($5.93M) | ($5.32M) | ($5.56M) | ($8.83M) | ($6.12M) | ($6.85M) | ($3.19M) | ($6.96M) | ($6.13M) |
| EPS - Basic | ($0.03) | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.03) | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.42M | $13.74M | $20.80M | $29.22M | $107.52M | $13.49M | $19.40M | $26.70M | $11.47M | $15.31M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $79.02M | $78.90M | $76.55M | $77.38M | $109.66M | $15.19M | $20.81M | $28.08M | $12.23M | $16.01M |
| Total Assets | $80.16M | $88.02M | $93.00M | $97.81M | $110.26M | $15.81M | $22.10M | $29.50M | $13.73M | $17.59M |
| Current Liabilities | $5.62M | $7.39M | $5.45M | $4.77M | $5.64M | $4.61M | $5.75M | $5.58M | $5.27M | $4.54M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.02M | $7.93M | $6.31M | $6.30M | $8.47M | $6.64M | $7.60M | $10.48M | $11.33M | $10.28M |
| Stockholders' Equity | $74.14M | $80.08M | $86.69M | $91.51M | $101.80M | $9.17M | $14.50M | $19.03M | $2.40M | $7.31M |
| Retained Earnings | ($166.91M) | ($160.42M) | ($153.61M) | ($148.29M) | ($136.79M) | ($129.61M) | ($123.49M) | ($107.82M) | ($102.09M) | ($95.13M) |
Cash Flow
| Line item | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.78M) | ($5.81M) | - | - | ($6.39M) | - | - | ($5.60M) | - | - |
| Investing Cash Flow | ($2.54M) | ($65.25M) | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | $6.2K | - | - | $1.00M | - | - | $10.77M | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 | Q2 '21 | Q1 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.1% | -6.7% | -5.7% | -5.7% | -8.0% | -38.7% | -31.0% | -10.8% | -50.7% | -34.8% |
| Return on equity | -8.8% | -7.4% | -6.1% | -6.1% | -8.7% | -66.8% | -47.2% | -16.8% | -289.5% | -83.8% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.06 | 10.68 | 14.04 | 16.21 | 19.43 | 3.29 | 3.62 | 5.03 | 2.32 | 3.53 |
| Quick ratio | 14.06 | 10.68 | 14.04 | 16.21 | 19.43 | 3.29 | 3.62 | 5.03 | 2.32 | 3.53 |
| Cash ratio | 1.14 | 1.86 | 3.82 | 6.12 | 19.05 | 2.92 | 3.37 | 4.78 | 2.18 | 3.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -556.5x | -312.9x | -361.1x | -306.1x | -264.6x | -260.5x | -281.8x | -187.3x | -248.7x | -213.6x |
| Equity multiplier | 1.08 | 1.10 | 1.07 | 1.07 | 1.08 | 1.72 | 1.52 | 1.55 | 5.71 | 2.41 |
| Liabilities / Assets | 0.08 | 0.09 | 0.07 | 0.06 | 0.08 | 0.42 | 0.34 | 0.36 | 0.82 | 0.58 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.7% | 14.4% | -0.3% | 19.0% | -25.8% | 10.3% | -17.2% | 8.1% | 19.0% | 10.9% |
| Net income growth (YoY) | -9.5% | 32.8% | 13.1% | 18.8% | -176.5% | 12.0% | -11.8% | 52.5% | 13.5% | 12.7% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -7.4% | -21.3% | 845.8% | 531.0% | 435.1% | 281.4% | 98.5% | 96.8% | -84.7% | -64.8% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TYME TECHNOLOGIES against the 5 most active filers in the same SIC group.